Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1/2 dose-escalation and expansion study investigating SAR439859+/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer
    Meeting Abstract

    Bardia, A.; Linden, H. M.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Celanovic, M.; Campone, M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC)
    Meeting Abstract

    Bardia, A.; Linden, H. M.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Celanovic, M.; Campone, M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)
    Meeting Abstract

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations
    Meeting Abstract

    Carlo, M. I.; Kemel, Y.; Breen, K.; Cadoo, K. A.; Walsh, M. F.; Abida, W.; Autio, K. A.; Danila, D. C.; Kampel, L. J.; Morris, M. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The Polycomb repressor complex 1 promotes recruitment of myeloid-derived suppressor cells and immune evasion during bone colonization in castration-resistant prostate cancer
    Meeting Abstract

    Su, W.; Zhang, B.; Han, H.; Chakraborty, G.; Zhou, B.; Su, J.; Yang, G.; Ouerfelli, O.; Rosen, N.; Scher, H. I.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • ARAF activates RAS by antagonizing its interaction with NF1
    Meeting Abstract

    Su, W.; Yaeger, R.; Na, N.; Hechtman, J.; Paroder, V.; Misale, S.; Han, S. W.; Abdel-Wahab, O. I.; McCormick, F.; Rosen, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Otto, J.; Cai, Y.; Chan, C.; D'Avino, D. R.; Collings, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Gluthathione peroxidase 2 downregulation in the PyMT mammary tumor model leads to an aggressive phenotype due to stimulation of angiogenesis and tumor stemness via HIF1 alpha signaling
    Meeting Abstract

    Ren, Z.; Liang, H.; Benard, O.; Suyama, K.; Albanese, J. M.; Norton, L.; Zheng, W.; Hazan, R. B.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity
    Meeting Abstract

    Razavi, P.; Li, Q.; Li, Z.; Brown, D. N.; Ping, C.; Shen, R.; Sanchez-Vega, F.; Schultz, N. D.; Baselga, J.; Scaltriti, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save